Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2025 09:15 ET | Source: Longeveron

Longeveron® to Attend BIO International Convention 2025

Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.
May 08, 2025 16:05 ET | Source: Longeveron

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.
March 20, 2025 09:00 ET | Source: Longeveron

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.
February 15, 2022 09:00 ET | Source: Neurocentria, Inc

Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD

WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit...